<DOC>
	<DOCNO>NCT00476151</DOCNO>
	<brief_summary>This multicenter , randomize , placebo-controlled , parallel group study EpiCept™ NP-1 Topical Cream ( amitriptyline 4 % /ketamine 2 % ) approximately 200 patient pain low extremity due diabetic nerve pain .</brief_summary>
	<brief_title>A Study Efficacy Safety Amitriptyline/Ketamine Topical Cream Patients With Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description>This phase II , multicenter , randomize , placebo-controlled , parallel group study EpiCept™ NP-1 Topical Cream ( amitriptyline 4 % /ketamine 2 % ) approximately 200 patient chronic pain low extremity due diabetic peripheral neuropathy ( DPN ) .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<mesh_term>Amitriptyline , perphenazine drug combination</mesh_term>
	<criteria>Adult patient chronic pain due diabetic peripheral neuropathy ( DPN ) least 6 month duration eligible average daily pain score &gt; 4 baseline week . Clinically significant intercurrent illness ( e.g. , endocrine , cardiac , hepatic , renal , neurologic , hematologic , skeletal ) investigator determines could interfere efficacy safety assessment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>DPN</keyword>
	<keyword>Diabetic</keyword>
	<keyword>Nerve Pain</keyword>
</DOC>